Unexpected Serious Toxicity With Chemotherapy and Antiangiogenic Combinations: Time to Take Stock!
- 15 March 2002
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (6) , 1446-1448
- https://doi.org/10.1200/jco.2002.20.6.1446
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid TumorsJournal of Clinical Oncology, 2002
- The role of the coagulation system in tumour angiogenesisThe Lancet Oncology, 2001
- SymposiaEuropean Journal Of Cancer, 2001
- Redefining the Target: Chemotherapeutics as AntiangiogenicsJournal of Clinical Oncology, 2001
- Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?Journal of Clinical Oncology, 2001
- Cisplatin Triggers Platelet ActivationThrombosis Research, 2000
- Anti-angiogenic agentsEuropean Journal Of Cancer, 2000
- GEMCITABINE PLUS CISPLATIN FOR ADVANCED TRANSITIONAL CELL CARCINOMA OF THE URINARY TRACT: A PHASE II MULTICENTER TRIALJournal of Urology, 2000
- Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agentsInvestigational New Drugs, 1997
- Severe vascular toxicity associated with cisplatin-based chemotherapyCancer, 1993